

May 27, 2014  
Nissan Chemical Industries, Ltd.

To whom it may concern:

#### Marketing License of Bravecto, Veterinary Medical Product in the USA

As of May 20, 2014, MSD Animal Health, known as Merck Animal Health in the United States and Canada announced veterinary medical product BRAVECTO™ chewable tablets for dogs have been granted marketing authorization in the USA, which contains a new ectoparasiticide for companion animals, fluralaner invented by Nissan Chemical, followed by the marketing license had been granted in EU in February 2014.

BRAVECTO has been developed by MSD Animal Health as a veterinary medical product; it provides unique immediate and persistent tick and flea killing activity for dogs for 12 weeks (8 weeks for *Amblyomma americanum* – lone star tick), longer than currently available once-monthly commercialized products.

The active substance of BRAVECTO, fluralaner belonging to the isoxazoline group possesses a new mode of action different from currently available once-monthly products, and Nissan Chemical supplies it to MSD Animal Health.

MSD Animal Health started the sales of BRAVECTO in European countries in April 2014, and plans to launch BRAVECTO in the USA in June 2014. MSD Animal Health endeavors to obtain marketing authorization in the other countries including Japan.

#### About MSD Animal Health

MSD Animal Health (Head quarter in New Jersey, the United States), the global animal health business unit of Merck & Co., Inc., is present in more than 50 countries, while its products are available in some 150 markets. MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services.